OriginCell is a biomedical equipment enterprise that develops tumor immuno-therapy solutions.
OriginCell is a biomedical equipment enterprise that develops tumor immuno-therapy solutions. It develops tumor therapies and cellular drugs through the use of the 10-phage display library, humanized antibody technology platform, and antibody discovery platform that enable their medical facilities to apply in cancer treatments.OriginCell was founded in 2014 and is headquartered in Shanghai, China.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 30, 2022 | Series A | ¥410M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Shanghai Gui Guo Assets Management Partnership | — | Series A |